Sarepta Therapeutics, Inc. — Q1 2022 Form 10-Q Summary
Business context and reporting period
Sarepta is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, gene therapy and other genetic medicines for rare diseases, including Duchenne muscular dystrophy (Duchenne), limb-girdle muscular dystrophies and other neuromuscular and central nervous system disorders. The filing covers the three months ended March 31, 2022; results are unaudited and are not necessarily indicative of full-year performance.
The company commercializes EXONDYS 51, VYONDYS 53 and AMONDYS 45 in the United States, all granted accelerated FDA approval. Its development pipeline includes more than 40 programs, with SRP-9001, SRP-9003 and SRP-5051 among the principal programs discussed.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Total revenue | $210.8 million | $146.9 million | Up 43% |
| Product revenue, net | $188.8 million | $124.9 million | Up 51% |
| Collaboration revenue | $22.0 million | $22.0 million | Flat |
| Total cost of sales and amortization | $31.6 million | $22.5 million | Up 40% |
| Gross profit and approximate gross margin | $179.2 million; 85.0% | $124.4 million; 84.7% | Margin broadly stable |
| Research and development | $194.3 million | $195.1 million | Essentially flat |
| Selling, general and administrative | $71.8 million | $71.1 million | Up 1% |
| Operating loss and approximate operating margin | $(86.9) million; (41.2)% | $(151.9) million; (103.4)% | Loss narrowed |
| Net loss and approximate net margin | $(105.0) million; (49.8)% | $(167.3) million; (113.8)% | Loss narrowed 37% |
| Net loss per share | $(1.20) | $(2.10) | Improved by $0.90 |
| Cash used in operating activities | $(101.2) million | $(180.4) million | Outflow improved |
Product revenue by product was $117.1 million for EXONDYS 51, $43.6 million for AMONDYS 45 and $28.1 million for VYONDYS 53. AMONDYS 45 benefited from a full quarter of sales following its February 2021 launch. SRP-9001 research and development expense increased to $91.6 million from $59.4 million, reflecting program advancement and trial activity.
Liquidity, cash flow and debt
| Balance-sheet item | March 31, 2022 | December 31, 2021 |
|---|---|---|
| Cash and cash equivalents | $1.234 billion | $2.116 billion |
| Short-term investments | $779.5 million | None reported |
| Restricted cash and investments | $9.7 million | $9.9 million |
| Total cash, cash equivalents, restricted cash and investments | $2.023 billion | $2.126 billion |
| Long-term debt | $1.099 billion | $1.097 billion |
| Working capital | $2.076 billion | $2.151 billion |
Cash decreased by $882.0 million during the quarter, primarily because the company invested $779.8 million in available-for-sale securities and used $101.2 million in operating activities. Financing activities provided $5.0 million from stock-option exercises and employee stock purchases. Management stated that available cash, cash equivalents, restricted cash and investments were sufficient to fund the current operating plan for at least the next twelve months.
Debt consisted principally of a term loan with a carrying value of $534.6 million and convertible debt with a carrying value of $564.2 million. The credit agreement requires consolidated liquidity of at least $100.0 million at each month-end and includes collateral and operating restrictions.
Material changes versus the prior comparable period
- Product revenue increased $63.9 million, driven by higher demand and the full-quarter contribution from AMONDYS 45.
- Cost of sales increased $9.1 million, including higher inventory costs and royalty payments, but gross margin remained approximately 85%.
- Operating loss narrowed by $65.0 million, primarily because of higher revenue and the absence of the $10.0 million BioMarin settlement and license charge recorded in Q1 2021.
- Net loss improved by $62.2 million despite a $1.7 million increase in net other expense, primarily associated with investment mark-to-market effects and debt interest.
- Operating cash outflow improved by $79.2 million, largely reflecting the lower net loss and more favorable changes in payables and accrued liabilities.
- The company shifted substantial cash into short-term investments, resulting in lower cash and higher investments compared with year-end 2021.
Guidance, outlook, commentary and risks
The filing does not provide quantitative full-year revenue or earnings guidance. Management expects to continue incurring significant operating losses at least through 2022 and anticipates that additional capital may eventually be required to support development, commercialization, manufacturing and regulatory obligations.
- Management expected to complete GMP runs for SRP-9003 in 2022, meet with the FDA regarding a potential pivotal trial and announce additional SRP-9001 data during 2022.
- All three commercial products remain subject to accelerated-approval post-marketing requirements and confirmatory studies. Failure to verify clinical benefit could result in regulatory restrictions or withdrawal of approval.
- Manufacturing commitments totaled approximately $1.301 billion, including $651.8 million due from April through December 2022. The company relies heavily on third-party manufacturers and has limited internal large-scale GMP capacity.
- The company may be obligated to make up to $4.0 billion of future development, regulatory, commercial and royalty milestone payments, generally contingent on successful milestones and therefore not recorded as liabilities.
- Potential option agreements could require up to $11.0 million of research milestone payments and $187.1 million of option payments if options are exercised.
- COVID-19 may continue to affect product infusions, payer reauthorizations, clinical-trial enrollment and data collection, manufacturing, supply chains and staffing.
- Material intellectual-property litigation includes the RegenXBIO and University of Pennsylvania patent case involving AAV manufacturing technology and litigation with Nippon Shinyaku concerning exon-53 patents, VYONDYS 53 and related contract claims. No material loss accrual was recorded, and management stated that no material loss range was estimable.
- Subsequent events include a modification of the CEO’s stock-option vesting terms, which management expects to cause a significant increase in stock-based compensation, and a 15-year, $307.4 million lease for a 288,000-square-foot facility in Bedford, Massachusetts.
Most important facts for investors to verify
- Whether growth in EXONDYS 51, VYONDYS 53 and AMONDYS 45 sales is sustained and translates into improving operating cash flow.
- Progress, clinical results, manufacturing readiness and regulatory timelines for SRP-9001, SRP-9003 and SRP-5051.
- Results and regulatory consequences of confirmatory trials required for the accelerated approvals.
- Cash burn, debt maturities, the $100 million liquidity covenant and the timing or terms of any future financing.
- Execution against approximately $1.3 billion of manufacturing commitments and the impact of the new Bedford facility lease.
- Potential financial and commercial effects of the RegenXBIO and Nippon Shinyaku litigation and other intellectual-property disputes.
- The impact of the CEO option modification on future stock-based compensation and dilution.
- Customer concentration, payer reimbursement, product-reserve estimates and reliance on third-party distributors and manufacturers.